Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Prof. Nakamura Renews Call for Establishment of Drug Discovery Support Organization
March 9, 2012
- Insulin Stockpiles Insufficient at Medical Facilities in Disaster-Hit Areas: JDS Survey
March 6, 2012
- Osaka Medical Center President Hori says “Once-Daily Xarelto is Easy to Take”
February 27, 2012
- JAS 2012 GL Calls for Consideration of Medication for Primary Prevention in Patients with LDL-C Levels Over 180 mg/dL
February 7, 2012
- Demand for Celecox Expected to Increase for Acute Pain Relief: Prof. Ishiguro
January 26, 2012
- Manufacturers Report on Patient Benefits of Oral RI Drugs
January 24, 2012
- JDS to Use NGPS Score for HbA1c in Clinical Practices from April
January 23, 2012
- A New Industry Could Be Created in the Field of Pre-Symptomatic Medical Intervention: Kyoto Univ. Prof. Kawakami
January 16, 2012
- Specialists Debate Pro, Cons of Early Pharm. Intervention in Dementia
January 16, 2012
- MD Studies Could Increase Development Success Rate to 30%: Prof. Sugiyama
December 20, 2011
- Kyushu University Professor Egashira Says Suppression of Vascular Inflammation Can Be Target for Development
November 30, 2011
- JDA Requests Additional Indication of Pustular Psoriasis for Humira
November 22, 2011
- JSMO Issues 33 Development Requests for Unapproved Drugs, Indications
November 22, 2011
- JUA Negative about OTC Switching of Propiverine Hydrochloride
November 17, 2011
- PSJ Preparing for Exchange of Views with JAMS on Switch-OTC Drug Candidates
November 15, 2011
- Teriparatide “Strongly Recommended” for Non-vertebral Fracture: JOS Draft GLs
November 7, 2011
- “No Major Ethnic Differences” in Pharmacokinetics of 3 Drugs Reported
November 1, 2011
- JSGM Calls for Elimination of GE Drug Refusal Option in Prescriptions
October 28, 2011
- JSGM Calls For Elimination of GE Drug Refusal Option in Prescriptions
October 27, 2011
- “No Major Differences” Between 4 AD Treatments; More Evidence Needed: Prof. Hanyu
October 20, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…